Trichomonas vaginalis: tratamiento y resistencia a nitroimidazoles
Bibliografía (204)
- et al.
An alternative keto acid oxidoreductase in Trichomonas vaginalis
Mol Biochem Parasitol
(1999) - et al.
Resistance to the nitroheterocyclic drugs
Acta Trop
(1994) - et al.
Characterisation and purification of pyruvate: ferredoxin oxidoreductase from Giardia duodenalis
Mol Biochem Parasitol
(1996) - et al.
Drug resistance and Giardia
Parasitol Today
(1993) - et al.
Metronidazole use in obstetrics and gynecology: A review
Am J Obstet Gynecol
(1983) Reductive activation of nitroimidazole in anaerobic microorganisms
Biochemical Pharm
(1986)- et al.
Three metronidazoleresistant strains of Trichomonas vaginalis from the United States
Am J Obstet Gynecol
(1980) - et al.
Isolation of Trichomonas vaginalis resistant to metronidazole
Lancet
(1980) Trichomonads, hidrogenosomes and drug resistance
Int J Parasitol
(1999)- et al.
Isolation of Trichomonas vaginalis resistant to metronidazole
Lancet
(1978)
Treatment failure in trichomoniasis and persistence of the parasites after Lactobacillus inmunotherapy; two case reports
Eur J Obstet Gynecol Reprod Biol
Trichomonas vaginalis and amplification of HIV- 1 transmission
Lancet
Trichomonas vaginalis and trichomoniasis
A new antibiotic, azomycin
J Antibiot
Metronidazole. A therapeutic review and update
Drugs
Activité de l’(hydroxy-2-éthyl)-1-méthyl-2-nitro-5-imidazole (8823 R.P.) vis-à-vis des infections expérimentales à trichomonas vaginalis
Ann Inst Pasteur
Trial of an antitrichomonal derivate of imidazole (8823 R.P.) Comptes Rendus Soc Franç Gynécol
Systemic treatment of human trichomoniasis with a derivative of nitro-imidazole, 8823 R. P
Br J Vener Dis
Nitroimidazole drugs-action and resistance mechanisms. I. Mechanisms of action
J. Antimicrob Chemother
Tinidazole, a new antiprotozoal agent: Effect on Trichomonas and other protozoa
Antimicrob Agents Chemother
Tinidazole – a new preparation for Trichomonas vaginalis infections. II. Clinical evaluation of treatment with a single oral dose
Br J Vener Dis
Comparison of ornidazole and tinidazole in single- dose treatment of trichomoniasis in women
Br J Vener Dis
An evaluation of tinidazole as single- dose therapy for the treatment of Trichomonas vaginalis
Med J Aust
Metronidazole and tinidazole in a single large dose for treating urogenital infections with Trichomonas vaginalis in man
Br J Vener Dis
Tinidazole, a potent new antiprotozoal agent
Antimicrob Agents Chemother
Tricomoniasis (Ponencia)
Treatment failure in Trichomonas vaginalis infections in females. I. Concentrations of metronidazole in plasma and vaginal content during normal and high dosage
J Antimicrob Chemother
Ornidazole: A new antiprotozoal compound for treatment of Trichomonas vaginalis infections
Br J Vener Dis
Secnidazole- a nitroimidazole with a prolonged serum halflife
J Antimicrob Chemother
First experiences with single- dose treatment of vaginal trichomoniasis with carnidazole (R25831)
Br J Vener Dis
Nitroimidazole: A new systemic trichomonacide
G Mal Infett Parassit
How suitable are available pharmaceuticals for the treatment of sexually transmited diseases? 1. Conditions presenting as genital discharges
Br J Vener Dis
Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and–resistant Giardia, Trichomonas, and Entamoeba spp
Antimicrob Agents Chemother
Mode of action of metronidazole an anaerobic bacteria and protozoa
Surgery
Hydrogenosomes in Trichomonas vaginalis
J Parasitol
The hydrogenosome
J Gen Microbiol
In vitro effect of tinidazole and furazolidone on metronidazole- resistant Trichomonas vaginalis
Antimicrob Agents Chemother
Treatment failure in Trichomonas vaginalis vaginitis
Genitourin Med
Further observations on strain sensitivity of Trichomonas vaginalis to metronidazole
Br J Vener Dis
Inactivation of metronidazole by aerobic organisms
J Antimicrob Chemother
Zinc and recalcitrant trichomoniasis
Lancet
Zinc, taurine and epilepsy
Arch Neurol
Plasma zinc levels with anticonvulsant therapy
Br J Clin Pharmacol
Trichomonal vaginitis resistant to metronidazole
Can Med Assoc J
Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles
Antimicrob Agents Chemother
Metronidazole resistance of Trichomonas vaginalis as a cause of treatment failure in trichomoniasis
Br J Vener Dis
Trichomonal vaginitis refractory to treatment: Case report
Genitourin Med
Nitroimidazole drugs- action and resistance mechanisms. II. Mechanisms of resistance
J Antimicrob Chemother
An in vitro metronidazole susceptibility test for trichomoniasis using the InPouch TV test
Genitourin Med
Cited by (12)
Flow cytometry evaluation of in vitro susceptibility of bovine isolates of Tritrichomonas foetus to metronidazole
2019, Veterinary ParasitologyCitation Excerpt :In our study, in addition to observing survival 48 h after treatment, we performed the subcultures of the trophozoites in Mz-free medium for 7 days in order to determine MLC. The values obtained indicate that all the bovine isolates studied are susceptible to Mz since resistance values were not observed in any of the conditions tested (extremely high concentrations) (Kulda et al., 1984; Vázquez et al., 2001). There are several methods to perform in vitro susceptibility tests that allow the rapid detection of new compounds with activity anti-T.
Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles
2016, European Journal of Medicinal ChemistryCitation Excerpt :However, there are no effective alternatives for patients who develop side effects or hypersensitivity, or when its use is contraindicated. Moreover, it is estimated that approximately 5–10% of diagnosed cases of trichomonosis are caused by nitroimidazoles-resistant isolates [42,43]. Therefore, the search for alternative drugs for the treatment of both parasitic pathologies is urgently needed.
Synthesis and in vitro and in vivo biological evaluation of substituted nitroquinoxalin-2-ones and 2,3-diones as novel trichomonacidal agents
2015, European Journal of Medicinal ChemistryCitation Excerpt :Metronidazole and tinidazole (5-nitroimidazole derivatives) are the only drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of trichomonosis [12] since the early 60s. Metronidazole presents a good pharmacokinetic profile [13] and high percentage of cure rates have been reported [14]; however, the development of resistance cases [15] and iatrogenic side effects [16] make necessary the search for novel chemical candidates to increase the therapeutic arsenal. On the other hand, quinoxaline derivatives are interesting molecules with diverse pharmacological properties.
The protocol of the Spanish Society of Obstetrics and Gynecology for the diagnosis and treatment of vulvovaginal infection. Update 2012
2013, Progresos de Obstetricia y GinecologiaUp to date in sexually transmitted infections: Epidemiology, diagnostic approaches and treatments
2004, Enfermedades Infecciosas y Microbiologia Clinica